Xarelto
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan. It inhibits free factor Xa, which interrupts the blood coagulation cascade, preventing both thrombin generation and thrombus formation. Xarelto inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Xarelto also has a number of other indications, including acute coronary syndrome and stroke prevention in atrial fibrillation, as well as ongoing development for ischemic stroke and chronic heart failure.
TABLE OF CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Xarelto : Stroke prevention in atrial fibrillation (SPAF)
21 Xarelto : Venous thromboembolism (VTE)
33 Xarelto : Chronic heart failure (CHF)
43 Xarelto : Acute coronary syndrome (ACS)
LIST OF FIGURES
14 Figure 1: Xarelto for SPAF – SWOT analysis
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xarelto for SPAF
16 Figure 3: Datamonitor Healthcare’s drug assessment summary of Xarelto for SPAF
18 Figure 4: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Xarelto for venous thromboembolism – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Xarelto for venous thromboembolism
28 Figure 7: Datamonitor Healthcare’s drug assessment summary of Xarelto for venous thromboembolism
30 Figure 8: Xarelto sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017–26
36 Figure 9: Xarelto for chronic heart failure – SWOT analysis
37 Figure 10: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
38 Figure 11: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
40 Figure 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
48 Figure 13: Xarelto for acute coronary syndrome – SWOT analysis
49 Figure 14: Datamonitor Healthcare’s drug assessment summary for Xarelto in acute coronary syndrome
50 Figure 15: Datamonitor Healthcare’s drug assessment summary for Xarelto in acute coronary syndrome
LIST OF TABLES
6 Table 1: Xarelto drug profile
8 Table 2: Xarelto pivotal trial data in SPAF
10 Table 3: Xarelto late-phase trial data in SPAF
13 Table 4: Xarelto ongoing late-phase clinical trial in SPAF
19 Table 5: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017–26
21 Table 6: Xarelto drug profile
23 Table 7: Xarelto pivotal trial data in venous thromboembolism
25 Table 8: Xarelto late-phase trial data in venous thromboembolism
31 Table 9: Xarelto sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017–26
34 Table 10: Xarelto drug profile
35 Table 11: Xarelto Phase III data in chronic heart failure
41 Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
44 Table 13: Xarelto drug profile
46 Table 14: Xarelto pivotal trial data in acute coronary syndrome
47 Table 15: Xarelto ongoing late-phase trial in acute coronary syndrome
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Eliquis 
Sign up to the